Literature DB >> 10437618

Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis.

C Passler1, C Scheuba, G Prager, K Kaserer, J A Flores, H Vierhapper, B Niederle.   

Abstract

BACKGROUND: Old age, reduced general condition and far advanced tumor stage associated with poor prognosis induced the belief that, apart from verifying the diagnosis of anaplastic thyroid carcinoma (ATC) by biopsy, no additional surgery would be justified. However, in some cases, an ultraradical approach was recommended in order to improve the quality of life and survival.
METHODS: These are the results of a retrospective analysis involving 120 patients subjected to restricted radical surgery (excising as much as possible of the tumor and local metastases, foregoing ultraradical removal of vital organs such as esophagus, larynx and trachea).
RESULTS: Irrespective of the surgical approach used, 6+/-2% of the patients were alive after 5 years (median survival time: 3.1 months). Patients without tumor residues (R0-resections; extending to soft tissue only; Kaplan-Meier estimate - cumulative survival 15+/-5%) had a significantly better prognosis than patients with tumor residues (R1/R2-resections; no patient survived 5 years; P<0.001). Tumor morphology (spindle cells, giant cells, mixed cells) or differentiated parts of the tumor as well as lymph-node involvement had no statistically significant impact on the prognosis.
CONCLUSIONS: In ATC, the objective should be to remove as much of the carcinoma as possible (in the ideal case, a thyroidectomy); if lymph nodes are affected, neck dissection should be the goal, if possible (restricted radical approach, improving quality of life). Ultraradical surgery to include segmental resection of larynx, trachea or esophagus do not seem to be indicated, as prolonged survival is questionable and quality of life is certainly diminished.

Entities:  

Mesh:

Year:  1999        PMID: 10437618     DOI: 10.1007/s004230050205

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  27 in total

1.  Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.

Authors:  Iwao Sugitani; Akira Miyauchi; Kiminori Sugino; Takahiro Okamoto; Akira Yoshida; Shinichi Suzuki
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

2.  European endocrine surgery in the 150-year history of Langenbeck's Archives of Surgery.

Authors:  Henning Dralle; A Machens
Journal:  Langenbecks Arch Surg       Date:  2010-03-09       Impact factor: 3.445

Review 3.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

4.  Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival.

Authors:  Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-14       Impact factor: 2.503

5.  Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.

Authors:  J Akaishi; M Onda; J Okamoto; S Miyamoto; M Nagahama; K Ito; A Yoshida; K Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-28       Impact factor: 4.553

Review 6.  Surgical options in undifferentiated thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

7.  Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy.

Authors:  Richard Crevenna; Georg Zettinig; Mohammad Keilani; Martin Posch; Manuela Schmidinger; Christian Pirich; Martin Nuhr; Michael Wolzt; Michael Quittan; Veronika Fialka-Moser; Robert Dudczak
Journal:  Support Care Cancer       Date:  2003-06-03       Impact factor: 3.603

8.  Tracheal stenting has minimal impact on survival in anaplastic thyroid carcinoma.

Authors:  Parameswaran Rajeev; Tarek Ezzat; Mark Slade; Gregory Paul Sadler; Radu Mihai
Journal:  World J Surg       Date:  2013-11       Impact factor: 3.352

Review 9.  Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?

Authors:  Vesna Bisof; Zoran Rakusic; Marija Despot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-03       Impact factor: 2.503

10.  Approach to the patient with anaplastic thyroid carcinoma.

Authors:  Robert C Smallridge
Journal:  J Clin Endocrinol Metab       Date:  2012-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.